Last reviewed · How we verify
Placebo of Pimecrolimus Cream, 1%
Placebo of Pimecrolimus Cream, 1% is a Small molecule drug developed by Glenmark Pharmaceuticals Ltd. India. It is currently in Phase 3 development for Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions.
This is a placebo formulation with no active pharmacological mechanism.
This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions.
At a glance
| Generic name | Placebo of Pimecrolimus Cream, 1% |
|---|---|
| Sponsor | Glenmark Pharmaceuticals Ltd. India |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
As a placebo of pimecrolimus cream, this product contains no active ingredient and serves as a control comparator in clinical trials. Pimecrolimus itself is a calcineurin inhibitor that would suppress T-cell activation, but the placebo formulation is inert and produces only non-specific effects.
Approved indications
- Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions
Common side effects
- Adverse events expected to be similar to vehicle/excipient effects only
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (PHASE3)
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetic Properties of IN-A002 Ointment in Healthy Adult Male Volunteers and Mild to Moderate Atopic Dermatitis Patients (PHASE1)
- Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis (PHASE3)
- Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca (PHASE2)
- Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis (PHASE3)
- Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba (PHASE2, PHASE3)
- Safety and Bioequivalence of Pimecrolimus Cream 1% and Elidel R in Treatment of Mild to Moderate Atopic Dermatitis (PHASE3)
- 1% Topical Pimecrolimus Cream for the Treatment of the Rash Associated With ERBITUX (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of Pimecrolimus Cream, 1% CI brief — competitive landscape report
- Placebo of Pimecrolimus Cream, 1% updates RSS · CI watch RSS
- Glenmark Pharmaceuticals Ltd. India portfolio CI
Frequently asked questions about Placebo of Pimecrolimus Cream, 1%
What is Placebo of Pimecrolimus Cream, 1%?
How does Placebo of Pimecrolimus Cream, 1% work?
What is Placebo of Pimecrolimus Cream, 1% used for?
Who makes Placebo of Pimecrolimus Cream, 1%?
What development phase is Placebo of Pimecrolimus Cream, 1% in?
What are the side effects of Placebo of Pimecrolimus Cream, 1%?
Related
- Manufacturer: Glenmark Pharmaceuticals Ltd. India — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Control arm in phase 3 clinical trials for atopic dermatitis or other inflammatory skin conditions
- Compare: Placebo of Pimecrolimus Cream, 1% vs similar drugs
- Pricing: Placebo of Pimecrolimus Cream, 1% cost, discount & access